STOCK TITAN

Celularity Inc. - $CELU STOCK NEWS

Welcome to our dedicated page for Celularity news (Ticker: $CELU), a resource for investors and traders seeking the latest updates and insights on Celularity stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Celularity's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Celularity's position in the market.

Rhea-AI Summary
Celularity's Halal Certified biomaterial products receive classification by SFDA for importation into Saudi Arabia
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.41%
Tags
none
-
Rhea-AI Summary
Celularity appoints Dr. Geoffrey Shiu Fei Ling to its Board of Directors, bringing expertise in regenerative medicine and stem cell therapy. Dr. Ling's outside perspective and deep understanding of cell-based treatments will help unlock the potential of placental-derived cells and tissues. Andrew von Eschenbach, M.D., steps down from the Board of Directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.92%
Tags
management
-
Rhea-AI Summary
Celularity to provide research support for Regeneron's targeted allogeneic CAR T-cell therapy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.04%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.71%
Tags
-
Rhea-AI Summary
Celularity Inc. (Nasdaq: CELU) and Verséa Ophthalmics, LLC announced an exclusive U.S. commercialization agreement for the distribution of Celularity’s BIOVANCE® and BIOVANCE® 3L Ocular products, targeting ocular surface disease and ocular surgical applications. The global persistent corneal epithelial defect management market is currently valued at $8.5 billion, and is expected to grow at an 18 percent compound annual growth rate (CAGR) through 2033, reaching a valuation of $44.49 billion, according to Future Market Insights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.71%
Tags
none
-
Rhea-AI Summary
Celularity Inc. (Nasdaq: CELU) to present therapeutic potential of human placental-derived biomaterials at ICBST23. Clinical case studies and benchtop data on proprietary extracellular matrices (ECM) will be showcased at the International Conference on Biomaterials Science and Tissue Engineering in Osaka, Japan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.71%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.93%
Tags
none
-
Rhea-AI Summary
Celularity Inc. has published preclinical data demonstrating that CRISPR-mediated tissue factor gene knockout in allogeneic stromal cells leads to lower tissue factor expression and reduced thrombotic effects. This could improve the safety of ASC-based cell therapy. The study showed that efficient gene editing can significantly reduce tissue factor activity without affecting critical cell functions. Celularity plans to use this strategy to progress their genetically modified cell therapy candidate APPL-001 in various clinical indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.68%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
none
Celularity Inc.

Nasdaq:CELU

CELU Rankings

CELU Stock Data

75.37M
9.49M
50.95%
14.67%
1.91%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
FLORHAM PARK

About CELU

Celularity, Inc. headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified natural killer (NK) cells, genetically-modified NK cells, T-cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs) targeting indications across cancer, infectious and degenerative diseases. In addition, Celularity develops and manufactures innovative biomaterials also derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it will be able to develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.